Target concentration intervention in oncology: where are we at?

Therapeutic Drug Monitoring
Mohamed SaleemJennifer H Martin

Abstract

Therapeutic drug monitoring (TDM) and more recently target concentration intervention (TCI) have been widely used in clinical practice for the optimization of drug treatment. TDM and TCI have been applied most frequently in the cardiovascular, respiratory, neurology, and infectious disease areas because the medications used here have both narrow therapeutic indices and a clear relationship between concentration and effect. However, apart from drugs such as methotrexate and 5-fluorouracil, the clinical application of TDM/TCI in oncology is minimal. An important reason for this is that a therapeutic index for most anticancer agents has not been established. However, in the last 20 years, relationships between plasma drug concentrations and clinical outcome have been defined for various chemotherapeutic agents. Defining concentration-effect relationships is also complicated by the fact that cancer is almost always treated with multiple drugs given in combination making the precise definition of the pharmacodynamics of individual agents difficult. The increase in patients with obesity and also those underweight adds to the complexity of effective oncology treatment. This review describes some of the evidence that supports the use o...Continue Reading

References

Jul 1, 1992·The Annals of Pharmacotherapy·M Gibaldi
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HorwichW F Hendry
Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L TrumpK D Tutsch
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J RatainM J Egorin
Jun 1, 1989·Clinical Pharmacokinetics·W E Evans, M V Relling
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B CamittaL Munoz
Oct 1, 1987·Clinical Pharmacokinetics·M J Moore, C Erlichman
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N GrafU Bode
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MilanoF Demard
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·B T SørensenA Jakobsen
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·P GuilletR Favre
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J JohansenR E Champlin
Feb 19, 1998·The New England Journal of Medicine·W E EvansC H Pui
Mar 27, 1999·Clinical Pharmacokinetics·S J Clarke, L P Rivory
Jun 26, 1999·British Journal of Clinical Pharmacology·N H Holford
Aug 10, 1999·Critical Reviews in Oncology/hematology·E Gamelin, M Boisdron-Celle
Oct 29, 1999·Journal of Cancer Research and Clinical Oncology·V R Nannan PandayJ H Beijnen
Jul 5, 2001·Breast Cancer Research and Treatment·Y MadarnasG A Bjarnason
Sep 21, 2001·British Journal of Clinical Pharmacology·E J BeggC M Kirkpatrick
Sep 21, 2001·British Journal of Clinical Pharmacology·A Johnston, D W Holt
Aug 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A FeliciA Sparreboom
May 24, 2003·Cancer Chemotherapy and Pharmacology·Lorraine D RalphChris Twelves
Jun 27, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H RubieUNKNOWN Pharmacology Group of the Société Française de Pédiatrie Oncologique
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Dec 18, 2003·British Journal of Clinical Pharmacology·Kellie A SlavieroLaurent P Rivory
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bin PengRenaud Capdeville
Jan 25, 2005·Therapeutic Drug Monitoring·D J TouwUNKNOWN Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring
Jun 16, 2005·Archives of Internal Medicine·Jennifer J GriggsGary H Lyman
Jul 29, 2005·Journal of Gastroenterology and Hepatology·Richard B Gearry, Murray L Barclay
Aug 27, 2005·Clinical Pharmacokinetics·Bin PengHorst Schran
Sep 27, 2005·Lancet·Marco ColleoniUNKNOWN International Breast Cancer Study Group
Apr 6, 2006·JAMA : the Journal of the American Medical Association·Cynthia L OgdenKatherine M Flegal
May 18, 2006·Breast Cancer Research and Treatment·Michelle ShayneUNKNOWN ANC Study Group

❮ Previous
Next ❯

Citations

Aug 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K C HourdequinR J Larson
May 9, 2013·Pharmacogenomics·André Bp van Kuilenburg, Jan Gerard Maring
Jun 15, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nicolas WidmerAlain Astier
Jun 1, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christophe BardinJos Beijnen
Jan 18, 2014·British Journal of Clinical Pharmacology·David Rey ArponJennifer H Martin
Sep 4, 2015·Biomarkers in Medicine·Laurent A DecosterdChantal Csajka
Jan 13, 2015·Cellular Oncology (Dordrecht)·Chiara PesentiMonica Miozzo
Dec 23, 2014·Bioanalysis·Cynthia M NijenhuisJos H Beijnen
Jan 31, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Cindy ChewTt Yeoh
Feb 20, 2013·Clinical Pharmacology and Therapeutics·J H Beumer
Jul 6, 2019·Critical Reviews in Oncology/hematology·Paul GougisRomain Coriat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved